6-(Difluoromethyl)-8-((1S,2S)-2-hydroxy-2-methylcyclopentyl)-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one | 2185859-59-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 6-(Difluoromethyl)-8-((1S,2S)-2-hydroxy-2-methylcyclopentyl)-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 英文别名: 6-(difluoromethyl)-8-[(1S,2S)-2-hydroxy-2-methylcyclopentyl]-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one
• CAS: 2185859-59-8
• 化学式: C₂₀H₂₇F₂N₅O₄S
• 分子量: 471.5
• InChiKey: QIEKHLDZKRQLLN-YWZLYKJASA-N

物化性质

• 沸点：
  634.0±65.0 °C(Predicted)
• 密度：
  1.47±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  124
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• CDK2/4/6 Inhibitors
  申请人：Pfizer Inc.

  公开号：US20180044344A1

  公开（公告）日：2018-02-15

  This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R 1 , R 2 , R 2A , R 2B , R 3 , R 4 , R 5A , R 5B , R 6 , R 7 , R 8 , R 9 , p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

  这项发明涉及一般式（I）的化合物及其药用盐，其中R1、R2、R2A、R2B、R3、R4、R5A、R5B、R6、R7、R8、R9、p、q和r如本文所定义，以及包含这些化合物和盐的药物组合物，以及使用这些化合物、盐和组合物治疗异常细胞增长，包括癌症的方法。
• [EN] DEUTERATED PYRIDOPYRIMIDINONES AND THEIR USE AS HIGHLY SELECTIVE CYCLIN-DEPENDENT KINASE 2 INHIBITORS<br/>[FR] PYRIDOPYRIMIDINONES DEUTÉRÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS HAUTEMENT SÉLECTIFS DE LA KINASE 2 DÉPENDANT DE LA CYCLINE
  申请人：ZENTAUR THERAPEUTICS INTERNATIONAL LTD

  公开号：WO2021249258A1

  公开（公告）日：2021-12-16

  The present invention relates to deuterated pyridopyrimidinone compounds and pharmaceutically acceptable salts thereof with inhibitory activity at cyclin dependent kinase 2 (CDK2) kinase, pharmaceutical composition comprising such compounds and methods of using such compounds for treating diseases associated with cell-cycle dysregulation.

  本发明涉及具有对细胞周期依赖性激酶2（CDK2）有抑制活性的氘代吡啶嘧啶酮化合物及其药学上可接受的盐，包含这种化合物的制药组合物以及使用这种化合物治疗与细胞周期失调相关的疾病的方法。
• CDK2/4/6 inhibitors
  申请人：Pfizer Inc.

  公开号：US10233188B2

  公开（公告）日：2019-03-19

  This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

  本发明涉及通式 (I) 的化合物 及其药学上可接受的盐，其中 R1、R2、R2A、R2B、R3、R4、R5A、R5B、R6、R7、R8、R9、p、q 和 r 如本文所定义；包含此类化合物和盐的药物组合物；以及使用此类化合物、盐和组合物治疗异常细胞生长（包括癌症）的方法。
• PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS
  申请人：Pfizer Inc.

  公开号：EP3497103B1

  公开（公告）日：2021-05-05
• [EN] PYRIDOPYRIMDINONE CDK2/4/6 INHIBITORS<br/>[FR] INHIBITEURS DE PYRIDOPYRIMIDINONE CDK2/4/6
  申请人：PFIZER

  公开号：WO2018033815A1

  公开（公告）日：2018-02-22

  This invention relates to compounds of general Formula (I), and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.